

## Oregon Drug Use Review Board

Office of Medical Assistance Programs  
State of Oregon  
November 12, 2002  
Meeting Minutes

The meeting was held at the Human Resources Building Rm 137CD  
500 Summer Street NE, Salem, Oregon.

### I. CALL TO ORDER

a. **Members present:** Gregory Johnson, MD, Patrick Bowman, RPh, John Meunch, MD, MPH, Raymond S. Lee, MD, Sharon Leigh, PharmD, Rickland Asai, DMD, and Robert Mendelson via conference phone at 2:15 PM

**Members absent:** Christina Heinrich, PharmD, Gerald Fairbanks, RPh, Robert Ingle, MD, Dean Haxby, PharmD and Cliff Singer, MD

**Staff Present:** Kathy Ketchum (OSU), Rose-Ellen Hope (FHSC), Thomas Drawbaugh (OMAP)

**Guests present:** Mike Lanning (Genentech), Dennis Sagendorf (Purdue), Jim Goddard (Shire), Tracy Davies (Eli Lilly), Jennifer Vu (OSU student), Sandra Thissell (Sepracor), Trina Clark (Eli Lilly), Paul Nielsen (Pharmacia)

The meeting was called to order by Ch. Johnson at 1:45.  
A quorum was not present.

**Action: All action items will be discussed with absent members. If there is disagreement, the item will be returned for added discussion at the next meeting.**

b. The agenda and minutes were approved with no corrections.

c. Conflict of Interest statements were reviewed.

d. There was no public comment.

### II. OLD BUSINESS

#### a. 2003 Meeting Dates

**Action: Meeting dates for 2003 are Tuesdays from 2:00 - 5:00 PM:**

**February 11, 2003**

**May 13, 2003**

**September 9, 2003**

**November 18, 2003**

### III. REPORTS

#### **a. Drug Utilization PMPM Report**

The Board reviewed the report.

#### **b. ProDUR Alert by Class**

The Board reviewed the report.

#### **c. Skeletal Muscle Relaxant Review**

The Board reviewed the report.

#### **d. ProDUR Report**

The Board reviewed the ProDUR Alert report, Clinical Alerts, and ProDUR criteria for skeletal muscle relaxants. There were no objections to the proposed changes to the ProDUR criteria.

#### **e. RetroDUR Report**

The Board reviewed the report. Ms. Hope reported that the Council is still recruiting for a physician to replace Cynthia Younger.

#### **f. Education Report**

Ms. Ketchum reported that recent topics of the monthly DUR Board Newsletter have included the Advair Review. The December issue will review new combination hormonal contraceptive products. January will focus on new generic mental health options. February may include a GAD review. Ms Ketchum also passed out an example of a targeted letter to prescribers of carisoprodol in preparation of the new quantity limit.

#### **g. Health Resources Commission Report**

Ms. Ketchum reported that the first four groups of the drugs (LA Opioids, PPIs, NSAIDs, Statins) continue with implementation. The second group of drugs (triptans and estrogens) are in review currently. ACE inhibitors, beta-blockers and calcium channel blockers will be reviewed by the same subcommittee. Subcommittees are currently forming for reviews of sulfonamides, urinary incontinence drugs and skeletal muscle relaxants.

Based upon feedback from pharmacists, a modification in the override process at the pharmacy level will be use of the DAW6 in lieu of DAW1 starting on Dec. 6.

#### **h. Pharmacy Program Update**

Mr. Drawbaugh reported that, at the direction of the legislative emergency board, the proposed drug reimbursement reduction to AWP-17% was withdrawn. The sedative and soma policies recommended by the Board will go into effect on December 6 with the new point of sale system. The pharmacy lock-in program is being phased in. There was some discussion regarding the lock-in program implementation, particularly around access to emergency antibiotics and issues of fair competition between different classes of pharmacy trade.

#### **IV. NEW BUSINESS**

##### **a. Pain advocacy and coverage issues**

Dr. Asai expressed concern regarding the seeming incongruent State policies that advocate for pain treatment yet don't pay for it.

**Action: Ms. Ketchum to follow-up and report recent activities on this topic from the Health Services Commission.**

##### **b. First SX**

Ms. Hope reported that First Health will be implementing a new point of sale claim processing system on December 6. This will replace the current main frame Oracle database system with a windows-based relational database system. The new system was needed to become NCPCP 5.1 compliant and HIPPA compliant by May 1, 2003. ProDUR criteria will be drawn initially from FirstDataBank and will also include criteria the DUR Board has recommended that is maintained by First Health.

##### **c. Proposed projects**

Ms. Ketchum brought forward several proposed DUR projects for the Board to consider. They include DUEs for the thiazolidinediones and glargine that would be modeled on the approach used for gabapentin. Additionally, the prior authorization criteria for growth hormone will be reviewed. A follow-up DUR of palivizumab is planned.

**Action: The College is to proceed with the projects.**

Next meeting is scheduled for February 12, 2003, at 2:00-5:00 PM. The meeting will be held at the Human Service Building.

The meeting was adjourned at 2:45 by Ch. Johnson.

Minutes respectfully submitted by Kathy Ketchum